Objective: To evaluate the stability of cabazitaxel diluted in 0.9% sodium chloride (NS) and stored in glass. Methods: A reverse-phase stability-indicating liquid chromatographic method was developed and validated before the study. The commercially available product was prepared according to the manufacturer's instructions, and further diluted in NS to obtain concentrations of 0.120 mg/mL and 0.240 mg/mL cabazitaxel and stored in glass under refrigeration and at 25ºC, all of them protected from light. The concentration of cabazitaxel was evaluated over a period of 21 days. Results: Physical stability: The visual inspection of the stored samples to 25ºC (0.120 mg/mL and 0.240 mg/mL) indicated appearance of a white precipitate in both cases on the day 2 of study. In the case of the refrigerated samples, a similar precipitate appears on the day 6 of the study for the 0.240 mg/mL concentration and on the day 21 for 0.120 mg/mL concentration. Chemical stability: The samples that stay physically stable have been evaluated by HPLC method obtaining in all determinations a remaining percentage >95%. Solutions of cabazitaxel were subjected to a forced degradation analysis. Conclusion: Solutions of cabazitaxel 0.120 mg/mL prepared in NS and stored in glass retained more than 95% of the initial drug concentration when stored for one day at 25ºC and for twenty days at 4ºC. Solutions of cabazitaxel 0.240 mg/mL prepared in the same conditions retained more than 95% of the initial drug concentration when stored for one day at 25ºC and for two days at 4ºC.
INTRODUCTION
Cabazitaxel is an antineoplastic agent that disrupts the micro tubular network of cells. It is indicated for men with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen. 1 As other members of its drug class, cabazitaxel has poor aqueous solubility. Due to its poor water solubility, cabazitaxel has been formulated in polysorbate 80 ( Figure 1 the injection concentrate with the complete content of the diluent vial to ensure a concentration of 10 mg/mL cabazitaxel in the resulting premix solutions. To compensate for loss of premix solution, due to foaming and adhesion to the walls of the vial both the injection concentrate and the diluent vial are overfilled. After reconstitution the premix solutions should be further diluted in 0.9% sodium chloride or 5% dextrose to a final concentration in a range of 0.100 to 0.260 mg/mL of cabazitaxel. Manufacturer stability data indicates that the reconstituted premix solutions are stable for 1 hour at room temperature and up to 24 hours under refrigeration, and diluted infusion solutions are stable for 8 hours at room temperature and up to 48 hours under refrigeration.
Liquid-chromatographic-tandem mass spectrometric (LC-MS/MS) methods to measure cabazitaxel plasma concentration have been described. 2, 3 but no method has been published about the stability of cabazitaxel in infusion for solution. The purpose of this study was to determine the stability of cabazitaxel over prolonged periods. Tests were performed on the reconstituted injection concentrate after dilution in 0.9% sodium chloride at two different concentrations, and stored in glass at room temperature and under refrigeration. Concentrations of diluted cabazitaxel infusion solutions (0.120 mg/mL, 0.240 mg/ mL cabazitaxel) were selected in accordance with the product information. Chemical stability was determined by using a stability-indicating high-performance-liquid chromatographic (HPLC) assay with ultraviolet detection. Physical stability was determined by visual inspection. The results can be used to assign a proper shelf life. [4] [5] [6] [7] 
MATERIALS AND METHODS
Cabazitaxel is commercialized by Sanofi-Aventis Groupe in Europe under the trade name Jevtana and by SanofiAventis US in the USA under the trade name Jevtana Kit. Each vial of Jevtana injection concentrate was aseptically reconstituted with the complete content of the diluent vial. The resulting premix solutions contained 10 mg/mL of cabazitaxel. The premix solution was diluted in NaCl 0.9 % to obtain a concentration of 0.3 mg/mL of cabazitaxel. Further dilutions were prepared in the same solvent to obtain four samples (2 x 0.120 and 2 x 0.240 mg/mL, respectively) and five standards of different concentrations (0.060, 0.120, 0.180, 0.240 and 0.300 mg/mL). The samples were stored in glass at controlled room temperature (25ºC, bacteriological and culture oven with temperature and time regulation and digital reading, Selecta (INCUDIGIT 19L 2001246) and under refrigeration (4ºC) protected from the light.
The standards were divided into different aliquot parts, stored in eppendorf tubes and frozen until each analysis day. HPLC-grade acetonitrile was obtained from SigmaAldrich. Sterile NaCl 0.9 % Fresenius Kabi was used as diluent. Deionised water was used throughout. Other chemical were of analytical grade.
Physical stability study
The physical stability of the samples was assessed by visual examination during all studied days for colour change and/or precipitation.
Chemical stability study
Cabazitaxel concentrations were determined by a stability-indicating HPLC method. HPLC analysis was performed at room temperature (~25ºC) using an Agilent Technologies, model LC 1220 Infinity including isocratic pump (maximum pressure 600 bar), manual injector valve and detector with variable wavelength (working wavelength at 235 nm). The signal from the detector was recorder and integrated with a PC HP Pro 3010 Desktop VN934EA; a Zorbax Eclipse XDB-C18, 4.6 x 250 mm, (5 μm) column was employed. The mobile phase consisted of acetonitrile: water (80:20, v/v) delivered at flow rate of 1.5 mL/min. The sample injection volume was 20 μL, and triplicate injections were performed for every sample. The retention time for cabazitaxel was 2.85 minutes. The initial concentration of cabazitaxel was defined as 100%, and subsequent sample concentrations were expressed as a percentage of the initial concentration. Stability of the drug was defined as retention of at least 95 % of the initial drug concentration.
Forced degradation analysis
Forced degradation is a degradation of new drug substance and drug product at conditions more severe than accelerated conditions. It is required to demonstrate specificity of stability indicating methods and also provide saninsight into degradation path ways and degradation products of the drug substance. 8, 9 Six different studies were carried out for this purpose over cabazitaxel solution stored under refrigeration: acid, base, heat, UV light, hydrogen peroxide and sodium hypochlorite.
RESULTS AND DISCUSSION

Physical stability
All solutions were initially clear and colourless and remained so for the duration of the study. Some sam- ples are physically unstable due to the appearance of a white precipitate depending of the concentration of solutions and the storage temperature (Table 1) .
Chemical stability
All the physically stable solutions were chromatographied. The experimental data were processed making use of the Stat graphics Centurion XVI program. The linearity of the method was evaluated at 5 concentration levels injected by triplicate varying from 0.060 mg/mL to 0.300 mg/mL. The calibration curve constructed from plots of peak area versus concentration of cabazitaxel reference standard was linear, the slope was 219002, the intercept 390520, the correlation coefficient (R 2 ) 0.9994, and the standard error of slope was 3142. Assay precision was determined with the signals obtained for cabazitaxel standard solutions; the results are showed in Table 2 .
On the other hand, Table 3 presents the results obtained of a multiple range test carried out with the signals corresponding to the standards and the analysed samples. This test applies a multiple comparison procedure to determine which means are significantly different from others. The lower half of the table shows differences estimated between each pair of means. The asterisk located next to 30 pairs indicates that these pairs show statistically significant differences with the 95.0% confidence level. At the top of the table, we have identified 5 homogeneous groups according to the alignment of the X's in columns. There are no statistically significant differences between those levels that share a same column of X's.
During the study period, the concentration in all study sample retained at least 97 % of the initial concentration of cabazitaxel.
Accelerated degradation analysis
The subsequent studies were made over cabazitaxel solution stored at 4 ºC. pH study. To eight aliquots of 500 µL of 0.120 mg/mL of cabazitaxel were added different amounts of HCl (0.1 M and 1 M) (100, 250, 500 and 1000 µL of both concentration). In all cases, the chromatograms showed two peaks, at 1.40 min corresponding to a degradation product and at 2.85 min corresponding to cabazitaxel. The same manner, to eight aliquots of 500 µL of 0.120 mg/mL of cabazitaxel was added different amounts of NaOH (0.1 M and 1 M) (100, 250, 500 and 1000 µL of both concentration). The results indicated that after 20 minutes storage in NaOH 1 M for all volumes added or after different times (between 20 -60 minutes) depending of volume added of NaOH 0.1 M only a trace of cabazitaxel was detected in the chromatograms. The higher difference observed in these chromatograms were the presence of diverse peaks corresponding to degradation products (at 1.40 and 1.97 min). Heat study. Three samples of 0.120 mg/mL of cabazitaxel were heat at different temperatures (40ºC, 60ºC, 80ºC) during different times (from 5 to 60 minutes). No significant changes were observed in the chromatograms in all cases. UV light. A sample of 0.120 mg/mL of cabazitaxel was subject to UV irradiation during one day. No significant changes were observed visually and in the chromatograms. Hydrogen peroxide. To twelve aliquots of 500 µL of 0.120 mg/mL of cabazitaxel were added different amounts (100, 250, 500 and 1000 µL) of H 2 O 2 of different concentrations (0.03, 0.3 and 3 %). Degradation of cabazitaxel occurs quickly with 3 % H 2 O 2 simultaneously appear the signal corresponding to the degradation product (R t = 1.40 min) which increase very much with the volume of H 2 O 2 added. Solutions with lower concentration of hydrogen peroxide degrade cabazitaxel more slowly, as can be seen in Figure 2a at the same time the signal corresponding to degradation product increase as can be seen in Figure 2b . Sodium hypochlorite. To twelve aliquots of 500 µL of 0.120 mg/mL of cabazitaxel were added different amounts (100, 250, 500 and 1000 µL) of NaClO of different concentrations (0.02, 0.2 and 2 M).Degradation of cabazitaxel occurs quickly with 2 M NaClO simultaneously appear the signal corresponding to the degradation product (R t = 1.40 min) which increase very much with the volume of NaClO added. Solutions with lower concentration of NaClO degrade cabazitaxel more slowly, as can be seen in Figure 2c at the same time the signal corresponding to degradation product increase as can be seen in Figure 2d . Also a signal corresponding to other degradation product appears to 1.97 minutes. Chromatographic spectra of developed method for pure cabazitaxel and for degraded drug after 75 minutes of forced degradation with 100 µl NaClO 0.2 M can be seen in Figure 2e and 2f.
CONCLUSION
Solutions of cabazitaxel 0.120 mg/mL prepared in NS and stored in glass retained more than 95% of the initial drug concentration when stored for one day at 25ºC and for twenty days at 4ºC. Solutions of cabazitaxel 0.240 mg/mL prepared in the same conditions retained more than 95% of the initial drug concentration when stored for one day at 25ºC and for two days at 4ºC. Test solutions and storage conditions were selected to observe normal clinical practice. Further investigations to establish the concentration limit for which the stability can be prolonged would enable an extended shelf life to be assigned to prepared infusions. This would then allow inclusion in dose-banding schemes. The method we describe presents enough accuracy and precision for being incorporated in a stability indicating study.
